Introduction
BRCA1 is a tumor suppressor gene associated with familial breast and ovarian cancer. Among familial cases of breast cancer, approximately 23% of the patients are born with a mutant BRCA1 allele (Sinilnikova et al., 2006) , and the tumors are associated with a loss of the second allele (Miki et al., 1994) . The most common deleterious mutations of BRCA1 are nonsense and frameshift mutations that result in a truncated protein.
However, not all BRCA1 variants have clear consequences. 36% of all BRCA1 mutations are missense mutations (Ruffner et al., 2001) . In the BIC database (http://research.nhgri.nih.gov/projects/bic/), 567 of the 1638 total mutations are missense variants of BRCA1. Individuals who have a BRCA1 missense mutation present a diagnostic dilemma, as the resultant BRCA1 protein may or may not be functional. Among the 567 BRCA1 missense mutations in the BIC database, 14 are deleterious and 27 are recorded as neutral. Though the BIC database may not have the latest results, only 7% of the BRCA1 missense mutations have a determined clinical phenotype. Apart from these several missense mutations of BRCA1 with defined clinical phenotype, the numbers of individuals with a specific variant are too few, and genetic segregation analysis fails to determine the consequences.
BRCA1 is known to be required in several cellular processes including: transcription, cell-cycle check point control, DNA damage repair and control of centrosome number (Chapman and Verma, 1996; Monteiro et al., 1996; Haile and Parvin, 1999; Moynahan et al., 1999; Xu et al., 1999; MacLachlan et al., 2000) . None of these processes, however, explain why BRCA1 mutations are specific for breast and ovarian cancers. BRCA1 depletion in mammary-derived cells leads to the formation of supernumerary centrosomes (Xu et al., 1999; Starita et al., 2004) . Centrosomes are non-membranous organelles that are important for the formation of the bipolar mitotic spindle that insures the proper segregation of chromosomes into two daughter cells (Nigg, 2002; Sluder and Nordberg, 2004) . Having exactly two centrosomes in dividing cells is essential for the formation of bipolar spindles, and thus for the appropriate segregation of chromosomes into progeny cells. Centrosome amplification will lead to improper chromosome segregation, aneuploidy, genomic instability and thus ultimately may lead to cancer. BRCA1 regulates centrosome duplication through its E3 ubiquitin ligase activity where it ubiquitinates gamma tubulin (Starita et al., 2004) and a gamma tubulin adapter protein (Sankaran et al., 2007) , and thereby prevents centrosome reduplication within the same cell cycle (Kais and Parvin, 2008) .
In an attempt to determine the significance of BRCA1 missense variants, some studies examined the effect of these mutations on the ubiquitin ligase activity of the protein. The missense mutation of zinc-coordinating residues, that affect the proper folding of the RING domain, inhibited the BRCA1-BARD1 interaction as well as the BRCA1-dependent ubiquitin ligase activity of the protein (Ruffner et al., 2001; Morris et al., 2006) . The inhibition of the ubiquitin ligase activity of BRCA1 was not only restricted to mutations of the zinccoordinating residues, but also M18T, T37R and L52F were inactive for the ubiquitin ligase (Morris et al., 2006) . It is known that the N-terminal region of BRCA1 interacts with several proteins (Wu et al., 1996; Jensen et al., 1998; Houvras et al., 2000; Pao et al., 2000) suggesting that this domain of BRCA1 participates in several other functions in addition to its known ubiquitin ligase activity. In a previous study, we investigated the effect of missense mutations in the N-terminal region of BRCA1 on its function in homologous recombination. In addition to the zinccoordinating residues, the variants M18T and T37R were inactive in the homologous recombination process (Ransburgh et al., 2010) .
In this study, we assess the effects of different BRCA1 missense mutations on centrosome duplication, a cellular process that is regulated by BRCA1 in mammary epithelial cells, and we discover variants that are deleterious in this biological process. Comparing the results of this study with prior analysis of homologous recombination, it is clear that different amino acid residues of BRCA1 differentially contribute to regulation of homologous recombination and to centrosome control.
Results and discussion
In this study, we tested the effects of 14 BRCA1 point mutations (M18T, I21V, C24R, C27A, I31M, T37R, C39Y, H41R, I42V, C44F, C47G, L52F, D67Y and R71G) on centrosome number in cultured cells. These mutations except one, C27A, have been identified in individuals with a family history of breast cancer and are listed in the BIC database. All of these variants are located in BRCA1 RING domain, and most have been assayed for enzymatic ubiquitin ligase activity of the protein (Morris et al., 2006) . In a previous study, we tested BRCA1 variants for their effect on homologous recombination (Ransburgh et al., 2010) . In this paper, we study the effects of these same missense mutations of BRCA1 in a tissue culture-based functional assay for centrosome control ( Figure 1a ). Consistent with our previous results, depletion of BRCA1 using a smallinterfering RNA specific for the 3 0 -UTR of the endogenous BRCA1 mRNA resulted in centrosome amplification. When BRCA1 was depleted by RNA interference, consistently 410% of cells had aberrant centrosome numbers ( Figure 1a ). Thus, we use 10% as the value for an abnormal phenotype. By comparison, transfection of a control resulted in a range of 2.0-5.5% (mean ¼ 3.6%) of cells with aberrant centrosome number. We thus set the high end of normal at 5.5%. Upon addition of the plasmid for expression of wild-type BRCA1 protein, the centrosome defect was corrected. Depleting BRCA1 and expressing BRCA1 variants by transfecting the different plasmids that express fulllength mutant BRCA1 protein affected centrosome number differently. Some missense mutants (M18T, C24R, C27A, C39Y, H41R, I42V, C44F and C47G) caused centrosome amplification, while others had an intermediate phenotype (D67Y, I31M, I21V or L52F) or no effect on centrosome control (T37R and R71G) ( Figure 1a) .
In most cases, when there was centrosome amplification the centrioles detected in the assay were all clustered. Strikingly, expression of the L52F mutant resulted in a phenotype that differed from the other mutants ( Figure 2 ). In 56% of the cells with centrosome amplification, the expression of this mutant resulted in paired centrioles instead of the commonly seen centriole clustering phenotype (Figure 1b ). This result indicated that BRCA1 might have a second function at the centrosome controlling centriole separation. The BRCA1(L52F) variant was functional for controlling centriole pairing, but was defective in controlling centrosome duplication.
Some of the residues that we tested are important in coordinating the zinc atoms that control the structure of the RING domain of BRCA1 (C24R, C27A, C39Y, H41R, C44F and C47G) (Brzovic et al., 2003) . Substitution of any of these residues would likely have a major effect on the structure of the protein that would affect the formation of the BRCA1/BARD1 heterodimer, a complex with an E3 ubiquitin ligase activity. Consistent with this expectation, replacing the endogenous BRCA1 with any of these variant BRCA1 proteins resulted in an increase in the number of cells with supernumerary centrosomes. In addition to the six variants tested at zinc-coordinating residues, two other variants were clearly deleterious in the centrosome duplication assay where more than 10% of the cells had abnormal centrosome numbers: M18T and I42V. Replacement of the endogenous BRCA1 with BRCA1 (M18T) resulted in 13.6% of the cells with abnormal centrosome amplification, and the BRCA1(I42V) resulted in 10.8% of the cells with supernumerary centrosomes.
Expression of four variants revealed intermediate phenotypes where more than 5.5% of the cells had abnormal centrosome numbers. Expression of D67Y, I31M, L52F and I21V resulted in a moderate effect on centrosome amplification with 6.4, 6.6, 9.0 and 8.8% of the cells having extra centrioles, respectively. By comparison, expression of BRCA1 variants T37R and R71G resulted in no effect on centrosome numbers (Figure 1a) .
To rule out the possibility that the centrosome phenotype was cell-line specific, we tested selected mutants (M18T, T37R, I42V and L52F) for effects on centrosome number in the MCF7 cell line Figure S2 ). The level of depletion of BRCA1 by transfection of the smallinterfering RNA was modest, probably due to poor transfection rates with the Hs578T cell lines used in this assay. As the detection of the centrioles using green fluorescent protein (GFP)-centrin was also dependent on transfection, only the transfected cells were counted, and thus the resulting centrosome number was robust.
We compared the results of centrosome control variants with the results of the homologous recombination assay (Ransburgh et al., 2010) . Even though all of the tested variants were clustered in the BRCA1 RING domain, some variants differentially affected the two assays (Table 1) . M18T mutant was deleterious in both assays. By comparison, BRCA1(I42V) functioned normally in the homologous recombination assay but was defective in the centrosome assay. I42V has been shown to have a normal ubiquitin ligase activity (Morris et al., 2006) , leading to the inference that mutation of I42V blocks the protein-protein interaction of BRCA1 with another protein that is required for the BRCA1 function in the control of centrosome number. Remarkably, the T37R variant, which is just five amino acid residues from isoleucine-42 and which reportedly has no ubiquitin ligase activity (Morris et al., 2006) , was deleterious in homologous recombination but functioned normally in the control of centrosome number. The amino acidspecific resolution between the homologous recombination assay and the centrosome regulation assay suggest an intricate network of protein-protein interactions that differ between the two BRCA1-dependent processes.
In this study we (1) developed an assay for determining the effect of specific single amino acid variants of BRCA1 on centrosome regulation; (2) identified a second function of BRCA1 in controlling the pairing of centrioles; and (3) identified specific residues required Figure 2 Centriole amplification and control of pairing upon the expression of BRCA1 variants. BRCA1 depletion caused centrosome amplification. Introduction of wild-type BRCA1 back to the breast cells restored the normal numbers of centrosomes per cell (top). Depleting BRCA1 and introducing a BRCA1 variant that is deleterious to the centrosome function results in centrosome amplification that is mostly seen as clustering of 44 centrioles per cell (middle). Depleting BRCA1 and introducing the L52F mutant resulted in centrosome amplification with a distinct pairing of the centrioles that was distinct from the other variants tested (bottom). Small-interfering RNA, GFP-centrin plasmid and BRCA1 point mutant plasmid were transfected into Hs578T breast cancer cells in the presence of Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. Cells were fixed 48 h post-transfection with methanol, stained in DAPI and then incubated with wheat germ agglutinin conjugated with Texas red (Invitrogen) to stain the cell membranes. Cells were washed and mounted in ProLong Gold antifade (ProLong, South Plainfield, NJ, USA). Centrioles were then counted by fluorescence microscopy using a Zeiss Axiovert 200M microscope. BRCA1 expression plasmid, pcDNA-5HA-BRCA1, as previously described (Scully et al., 1997; Chiba and Parvin, 2002) and site-specific point mutations identified on the Breast Cancer Information Core (BIC) were generated using the QuikChange kit from Stratagene (Santa Clara, CA, USA). GFP-Centrin 2 plasmid was used to mark the centrioles (D'Assoro et al., 2001) . The 3 0 -untranslated region (UTR) of BRCA1 was targeted with small-interfering RNA with the sequence 5 0 -GCUCCUCUCACUCUUCAGU-3 0 specific for nucleotides 80 780-80 798 of the BRCA1 gene (accession number AY273801). The control oligonucleotide targets luciferase mRNA (5 0 -3 0 , UCGAAGUAUUCCGCGUACGTT) (Easton et al., 2007) , and the rest fall into the category of variants of unknown clinical consequence. Our assay showed C44F to be deleterious to the control of centrosome duplication and D67Y to be of intermediate phenotype. With regard to the D67Y, it might be judged to be at the high end of normal, as the centrosome amplification due to its expression was modest. These results with these two variants of known cancer predisposition indicate a correlation between this centrosome duplication assay and cancer predisposition. R71G, however, had full activity in the centrosome assay. This mutant is cancer associated due to a defect in splicing that cannot be identified by our assay that utilizes already spliced complementary DNA (Vega et al., 2001) . The BRCA1(R71G) protein, once made, apparently has normal function with regard to centrosome duplication (this study) and homologous recombination (Ransburgh et al., 2010) . Thus, combining the functional analysis revealed by the two cellular assays, the centrosome duplication assay and the homologous recombination assay, with the genetic and the clinical analysis of the mutants could potentially be important in the counseling process of women holding such missense mutations. As an example, the M18T variant trends to deleterious based on genetic segregation analysis, but the measure is not sufficiently significant to make a clinical prediction (Easton et al., 2007) . When taking into account the defect of BRCA1(M18T) in controlling centrosome duplication and in regulating homologous recombination, it is likely that this variant is in fact a cancer predisposing mutant. Functional assays that are capable of measuring the effect of variants on the protein activity can help define the pathogenicity or neutrality of a specific variant, and thus are important initial steps in helping physicians reach a clear understanding of the risk level of carrying a certain mutation in the BRCA1 gene. Clearly, more work is required to determine whether the results from BRCA1 biological functional assays translate into clinical predictors of tumor likelihood, but an important first step is cataloging many of these variants in functional assays, such as centrosome duplication control.
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